We report a 62-year-old female liver transplant patient who presented with sirolimus (SIR)-related pneumonitis (SIP) treated with a switch to everolimus (EVER). At 13-month follow-up, the patient is on EVER monotherapy with no recurrence of SIP. Despite common mechanisms of action, the safety profile of EVER is different from SIR, and a switch from SIR to EVER should be contemplated in cases of SIP to allow patients to benefit from the antifibrotic properties of antiproliferative immunosuppressants.
|Autori:||DE SIMONE, P; Petruccelli, S; Precisi, A; Carrai, P; Doria, R; Menichetti, F; Filipponi, Franco|
|Titolo:||Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report|
|Anno del prodotto:||2007|
|Appare nelle tipologie:||1.1 Articolo in rivista|